The Food and Drug Administration (FDA) approved the oral antiviral Paxlovid for the treatment of mild to moderate COVID-19 in adults who are at high risk for progression to severe COVID-19 on May 25. Paxlovid packaged under the emergency use authorization (EUA) will continue to be available to ensure access for adults and treatment of eligible children ages 12-18 who are not covered under new FDA approval. Because of the importance of reducing the risk of significant drug-drug interactions with Paxlovid, the approved label and authorized Fact Fact Sheet for Health Care Providers for the Paxlovid EUA come with a boxed warning with instructions for prescribers. Prescribers should review all patient medications prior to prescribing.
